NCT05918198 is a Phase 2 clinical trial of Ven+CAG in Acute Myeloid Leukemia, sponsored by Peking University People's Hospital.

Who is sponsoring NCT05918198?

NCT05918198 is sponsored by Peking University People's Hospital.

What drugs are being tested in NCT05918198?

Interventions in NCT05918198: Ven+CAG.

What condition does NCT05918198 study?

NCT05918198 studies Acute Myeloid Leukemia.

Is NCT05918198 still recruiting?

NCT05918198 is currently status unknown. Last updated 21 November 2023.

Last reviewed 2023-11-21 · How we verify

NCT05918198

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia

Status unknown Phase 2 Last updated 21 November 2023

What this trial tests

Phase 2 trial testing Ven+CAG in Acute Myeloid Leukemia in 52 participants. Status unknown.

Timeline

1 February 2023

Primary endpoint
31 December 2024

31 December 2025

Quick facts

Lead sponsor	Peking University People's Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	52
Start date	1 February 2023
Primary completion	31 December 2024
Estimated completion	31 December 2025
Sites	1 location across China

Drugs / interventions tested

Ven+CAG — full drug profile →

Conditions studied

Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →

Sponsor

Peking University People's Hospital

Who can join

Adults 18 to 75, any sex, with Acute Myeloid Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to test the safety and efficacy of venetoclax plus CAG regimen in refractory/relapsed acute myeloid leukemia patients.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Mitochondria and Acute Leukemia: A Clinician's Perspective.
Iyer P, Jasdanwala SS, Bhatia K, Bhatt S. · · 2024 · cited 6× · PMID 39273651 · DOI 10.3390/ijms25179704
Venetoclax: A Game Changer in the Treatment of Younger AML Patients?
Molica M, Perrone S, Federico V, Alati C, et al · · 2023 · cited 3× · PMID 38201501 · DOI 10.3390/cancers16010073

Verify or expand the search:

Other recruiting trials for Acute Myeloid Leukemia

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT06782542 — Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for I · Phase 2 · recruiting
NCT07177079 — High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML · Phase 1 · recruiting
NCT07384715 — First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod · Phase 1 · recruiting
NCT07107126 — Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes · Phase 1 · recruiting

Other Peking University People's Hospital trials

Trials by the same sponsor.

NCT07535645 — Baricitinib for Post-HSCT Persistent Thrombocytopenia · Phase 1, PHASE2 · not yet recruiting
NCT07516002 — Immunoglobulin Efficacy and Immune Profiling in Antibody Immunodeficiency · not yet recruiting
NCT07294339 — A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positiv · NA · not yet recruiting
NCT07500441 — Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML · recruiting
NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05918198 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University People's Hospital
Last refreshed: 21 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05918198.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing